Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Karam JA, et al. Among authors: zurita aj. Nat Commun. 2023 May 10;14(1):2684. doi: 10.1038/s41467-023-38342-7. Nat Commun. 2023. PMID: 37164948 Free PMC article. Clinical Trial.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Aparicio AM, et al. Among authors: zurita aj. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6. Clin Cancer Res. 2013. PMID: 23649003 Free PMC article.
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Liu XD, et al. Cancer Immunol Res. 2015 Sep;3(9):1017-29. doi: 10.1158/2326-6066.CIR-14-0244. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014097 Free PMC article.
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.
Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM. Bilen MA, et al. Among authors: zurita aj. Oncologist. 2015 Oct;20(10):1140-8. doi: 10.1634/theoncologist.2015-0143. Epub 2015 Aug 25. Oncologist. 2015. PMID: 26306901 Free PMC article. Clinical Trial.
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. Jonasch E, et al. Among authors: zurita aj. Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676. Ann Oncol. 2017. PMID: 28049139 Free PMC article. Clinical Trial.
77 results